Antitrust Allegations Against GoodRx Highlight Tensions in Drug Price Agreements

In a series of antitrust class actions, independent pharmacies have accused GoodRx of engaging in practices that they argue invite price-fixing among several pharmacy benefit managers (PBMs). The legal actions were initiated with a complaint filed on November 1 in the U.S. District Court for the Central District of California, which claims that GoodRx orchestrated an unlawful price-fixing agreement. According to the allegations, this arrangement was designed to suppress the prices paid to independent pharmacies for generic drugs. For more detailed information, refer to the original article. However, please note that the article is paywalled, which may restrict access to the complete details of the case.